What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @RichardPAConway: Don't stop hydroxychloroquine in SLE, even when doing well. Associated with ⬆️flare risk. x2 ev

      Richard Conway RichardPAConway

      4 years ago
      Don't stop hydroxychloroquine in SLE, even when doing well. Associated with ⬆️flare risk. x2 even when in remission. Abstr#0959 #ACR21 @RheumNow https://t.co/1gGx0V5oxk
      1133 MACE events in Oral Surveillance study - Tofa use in high risk pts had more MACE events than TNFi use. Abstr# 0958

      Dr. John Cush RheumNow

      4 years ago
      1133 MACE events in Oral Surveillance study - Tofa use in high risk pts had more MACE events than TNFi use. Abstr# 0958 #ACR21 Problems with the gimmish are: - Older patients, w/ Hi CV Risk - 50% prednisone use - Use of TNFi as comparator (effective at lowering CV risk) https://t.co/lzIyhgzvRe
      RT @RHEUMarampa: The strawberry🍓gums of granulomatosis with polyangiitis! (Note: not always so florid)
      @RheumNow #ACR

      sheila RHEUMarampa

      4 years ago
      The strawberry🍓gums of granulomatosis with polyangiitis! (Note: not always so florid) @RheumNow #ACR21 #RheumTwitter #MedTwitter https://t.co/qDfGJ5JeWz
      RT @doctorRBC: ⭐️IR for MACE, MI, non-fatal MI numerically ⬆️ in Tofa vs. TNFi
      ⭐️HR for MACE/MI/stroke >

      Robert B Chao, MD doctorRBC

      4 years ago
      ⭐️IR for MACE, MI, non-fatal MI numerically ⬆️ in Tofa vs. TNFi ⭐️HR for MACE/MI/stroke >1 for Tofa vs. TNFi ⭐️Risk factors: Smoking, ASA use, Age>65, men ⭐️Pts without risk factors, IR for MACE were similar Abs#958 #ACR21 @RheumNow #ACRBest https://t.co/xA3aGu5Sqi https://t.co/VnPHBhrmdx
      RT @drdavidliew: okay, so let's look at the #ACR21 plenary as we go

      so a reminder - FDA-mandated phase 3b/4 safety endp

      David Liew drdavidliew

      4 years ago
      okay, so let's look at the #ACR21 plenary as we go so a reminder - FDA-mandated phase 3b/4 safety endpoint study specifically looking at patients >50yo with at least one other CV risk factor today we're looking at MACE: that's CV death (excl PE), MI, stroke ABST0958 @RheumNow https://t.co/9U8Sahb9Q7
      RT @Janetbirdope: Vitamin D ⬇️incident autoimmune diseases & so do fatty acids but latter is not stat signif. 25

      Janet Pope Janetbirdope

      4 years ago
      Vitamin D ⬇️incident autoimmune diseases & so do fatty acids but latter is not stat signif. 25k older adults with factorial design, no interaction. ? Buy vit D stock @RheumNow #ACR21 #ACRBest VITAL trial abst#0957 https://t.co/Qk3VwNOZie
      RT @drdavidliew: Can vit D, omega-3 fatty acids prevent autoimmune dx development, even in non-deficient people?
      (some p

      David Liew drdavidliew

      4 years ago
      Can vit D, omega-3 fatty acids prevent autoimmune dx development, even in non-deficient people? (some plausibility, no other meds can) vit D *might* have an effect, esp post-2y cautious interest seems okay! extension worth looking at VITAL trial add-on #ACR21 ABST0957 @RheumNow https://t.co/H5aF8Vl79u
      RT @KDAO2011: Can vit D and omega3 prevent autoimmune dz?
      25,871 adult pts randomized:vit D 2000 IU daily, omega 3 (1 g/

      TheDaoIndex KDAO2011

      4 years ago
      Can vit D and omega3 prevent autoimmune dz? 25,871 adult pts randomized:vit D 2000 IU daily, omega 3 (1 g/d), combo, PCB and followed 5 yrs Vit D & combo showed statistical sig over time, omega3 showed a favorable trend Abst#0957 #Plenary #ACRbest @rheumnow https://t.co/moMCm9IJmO
      RT @AurelieRheumo: Take your supplements 🐠 fish oil and Vit D! VITAL RCT presented by @karen_kc123 shows Vit D +/-n-3

      Aurelie Najm AurelieRheumo

      4 years ago
      Take your supplements 🐠 fish oil and Vit D! VITAL RCT presented by @karen_kc123 shows Vit D +/-n-3 fatty acid ⬇️ incidence of AID compared to PBO. Promising although AID were self reported! @RheumNow #ACR21 #Abst0957 https://t.co/xdEdKuwXci #ACRBest https://t.co/zWrr9oC7F5
      RT @_Castillo_Pedro: Interesting study with Dr. Julia Manasson on gut and skin microbiome in monozygotic twins discordan

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Interesting study with Dr. Julia Manasson on gut and skin microbiome in monozygotic twins discordant for psoriatic disease. (red = Psoriatic). Gut ruminococcus bromii virtually absent in psoriatic pts. Eager to see further studies! #ACR21 Abst#0944 @RheumNow https://t.co/zrZPBAjh5p
      RT @MeralElRamahiMD: Clinical Pearl at @ACR21
      Is patchy tongue erythema + angular chelitis representative of Sjogren's o

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Clinical Pearl at @ACR21 Is patchy tongue erythema + angular chelitis representative of Sjogren's or oral candidiasis? Beware: Oral candiasis is a mimic of Sjogren's tongue. Differentiate by asking if burning of tongue. If so, not Sjogren's -- start PO antifungal! @RheumNow https://t.co/FbdiX8PFKV
      RT @bella_mehta: I honestly find Vit D literature confusing! VITAL RCT omega3 and vit D in preventing autoimmune disease

      Bella Mehta bella_mehta

      4 years ago
      I honestly find Vit D literature confusing! VITAL RCT omega3 and vit D in preventing autoimmune diseases. They seems to work?🧐The confidence intervals just shy of 1.00...I am still skeptical..but keeping vit D normal doesnt hurt I guess....#ACR21 @rheumnow abst#0957 https://t.co/QFcz2zK4Ic
      RT @synovialjoints: Physician global score was the strongest predictor of future flares in AS patients with TNFi dose ta

      Dr. Antoni Chan synovialjoints

      4 years ago
      Physician global score was the strongest predictor of future flares in AS patients with TNFi dose tapering. 29 (27%) flared at 2/3 of standard dose, 21 (20%) at 1/2 dose, 29 (27%) at 1/3 dose and 27 (25%) after discontinuation @RheumNow #ACR21 Abst#0929 https://t.co/pIzLgexe3k https://t.co/UM9cGLiYl7
      RT @MeralElRamahiMD: Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid.

      Sphingomyelins &

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid. Sphingomyelins & phosphatidyl-cholines/ethanolamines had the greatest separation power to classify RA + PsA samples. These lipid markers may have clinical utility if validated. #ACR21 @Rheumnow https://t.co/ktKRypTtlE
      RT @uptoTate: SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 sub

      Dr. Rachel Tate uptoTate

      4 years ago
      SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 subgroups. Can subtype pre-determine tx efficacy/response? Abs 0917 #ACR21 #RheumNow @RheumNow https://t.co/FKpCqXpobM https://t.co/WbjjyTIaiG

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×